Skip to main content
main-content

Latest from Medicine Matters oncology

Latest headlines

20-09-2020 | ESMO 2020 | Conference coverage | News

IMpassion130: ‘Clinically meaningful’ OS boost with atezolizumab in PD-L1-positive advanced TNBC

The final overall survival results of the IMpassion130 trial continue to support the first-line use of atezolizumab plus nab-paclitaxel in PD-L1-expressing patients with metastatic triple-negative breast cancer.

20-09-2020 | ESMO 2020 | News | Article

Consolidation nivolumab–ipilimumab fails to boost limited-stage SCLC survival after CRT

ETOP/IFCT 4-12 STIMULI findings do not support the use of consolidation nivolumab plus ipilimumab for limited-stage small-cell lung cancer patients who have completed chemoradiotherapy and prophylactic cranial irradiation.

18-09-2020 | FDA | News

FDA issues alert on atezolizumab–paclitaxel duo in breast cancer

Click through for the details of this announcement

18-09-2020 | FDA | News

Pralsetinib gets FDA go-ahead for RET fusion-positive lung cancer

Click through to read more

17-09-2020 | Immunotherapy | News

ICI therapy tied to reduced second primary cancer risk

People with cancer who receive treatment with immune checkpoint inhibitors may have a reduced risk for a second primary cancer, report French researchers.

16-09-2020 | Breast cancer | News

ctDNA accurately identifies breast cancer targeted therapy candidates

Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.

Feature content

28-07-2020 | Renal cell carcinoma | At a glance | Article

At a glance: The CheckMate RCC trials

A quick-reference guide to the CheckMate trials investigating the anti-PD-1 agent nivolumab, as monotherapy or in combination with the anti-CTLA-4 agent ipilimumab, in patients with renal cell carcinoma.

20-04-2020 | Prostate cancer | Brief review | Article

Promising immunotherapies for advanced prostate cancer: playing catch-up?

Abhishek Srivastava and Neal Shore survey upcoming trials and promising new immunotherapies for advanced PCa, while highlighting some of the successes in PCa immunotherapy.

16-12-2019 | Renal cell carcinoma | Video | Article

Axel Merseburger: Recent developments in metastatic renal cell carcinoma

Axel Merseburger provides an overview of the most promising trials and biomarkers in renal cell carcinoma at ESMO 2019.

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA.

Get the latest content delivered to your inbox

Register with Medicine Matters to start receiving our weekly newsletter now!

Image Credits